Comment on

• Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.

  Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, Park K, Kitabayashi N, MacDonald TY, Sheikh K, Vuong T, Guiducci C, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Hussain WM, Ramos AH, Winckler W, Redman MC, Ardlie K, Tewari AK, Mosquera JM, Rupp N, Wild PJ, Moch H, Morrissey C, Nelson PS, Kantoff PW, Gabriel SB, Golub TR, Meyerson M, Lander ES, Getz G, Rubin MA, Garraway LA. Barbieri CE, et al. Nat Genet. 2012 May 20;44(6):685-9. doi: 10.1038/ng.2279. Nat Genet. 2012. PMID: 22610119 Free PMC article.
• The mutational landscape of lethal castration-resistant prostate cancer.

  Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA. Grasso CS, et al. Nature. 2012 Jul 12;487(7406):239-43. doi: 10.1038/nature11125. Nature. 2012. PMID: 22722839 Free PMC article.